Insider filing · ALMS

Srinivas Akkaraju bought $1.5M of Alumis (ALMS)

Executed Nov 18 2025, disclosed Nov 20 2025, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Nov 19 2025), the stock returned +73.6% (delay-adjusted); from the execution session (Nov 18 2025), +77.8%. Derived: entry at the session's open, exit at the close 20 sessions later.

SA Srinivas Akkaraju Director profile →

Srinivas Akkaraju (Director) filed 12 Form 4 reports in the trailing twelve months (12 purchases, 1 sale, 2 filed past the two-business-day deadline), most often in Alumis Inc. (ALMS). Across 11 priced purchase filings, the average 21-session return was +37.1% from execution and +27.8% from disclosure (delay-adjusted; derived). The largest single filing was $18.8M of SRRK (500,439 sh across 6 lots, as filed), executed Oct 3 2025.

ALMS Alumis Inc. ALMS · Healthcare · 24 filings in 24 months ticker →

Healthcare · Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disor…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→